Compare Liberty Media Corporation Series C Liberty Formula One Common Stock (FWONK) vs Ionis Pharmaceuticals Inc. Common Stock (IONS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Liberty Media Corporation Series C Liberty Formula One Common Stock vs Ionis Pharmaceuticals Inc. Common Stock — how do they compare? Liberty Media Corporation Series C Liberty Formula One Common Stock trades at $90.85 (market cap $23.11B), while Ionis Pharmaceuticals Inc. Common Stock trades at $42.5 (market cap $7.04B). The key difference: Liberty Media Corporation Series C Liberty Formula One Common Stock is far larger — about 3.3× Ionis Pharmaceuticals Inc. Common Stock's market cap, and Liberty Media Corporation Series C Liberty Formula One Common Stock is trading nearer its 52-week high, Ionis Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Media Corporation Series C Liberty Formula One Common Stock for 0 Days and Ionis Pharmaceuticals Inc. Common Stock for 0 Days on average.
| FWONK | IONS | |
|---|---|---|
Market Cap | $23.11B | $7.04B |
Volume | 3,394,596 | 2,977,440 |
Sector | Media | Health |
52-Week High | $106.66 | $86.50 |
52-Week Low | $81.42 | $42.38 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $26.57B | $6.60B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Liberty Media Corporation Series C Liberty Formula One Common Stock
Liberty Media Corporation's Series C Liberty Formula One common stock is a tracking stock reflecting the economic performance of the Formula One Group, which holds Liberty Media's interests in Formula 1 racing, MotoGP, and related minority investments.
Read more on FWONK →About Ionis Pharmaceuticals Inc. Common Stock
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →
